That figure is the headline outcome from pharmaceutical-grade retatrutide and is the benchmark against which any non-trial source has to be measured (with the obvious caveat that non-trial sources have no comparable outcome data because they are not run as trials)
(Phase 2 anchor trial: 24.2% body weight loss at 48 weeks on 12mg, n=338, dose-response across 1mg/4mg/8mg/12mg arms.) Eli Lilly and Company
Sodium glucose cotransporter 2 inhibitors and gout risk: a sequence symmetry analysis
In one of the new clinical trials, Wharton and other researchers tested a higher-dose version of the drug, 25 milligrams rather than 14 milligrams, which is the highest dose Rybelsus comes in
5 Smoothies to Help Regulate Blood Sugar Levels 1
Description Table of Contents Methodology GLP-1 Receptor Agonist Market size was valued at USD 44.5 Billion in 2023 and is projected to reach USD 95.4 Billion by 2031 , growing at a CAGR of 10.3% during the forecast period 2024-2031